XML 70 R57.htm IDEA: XBRL DOCUMENT v3.19.1
License agreements - Syros (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 08, 2018
USD ($)
$ / shares
Jan. 01, 2018
USD ($)
$ / shares
shares
Jan. 31, 2018
USD ($)
item
$ / shares
shares
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
License agreements            
Long term investment       $ 120,188   $ 99,199 [1]
Research and development expense       270,545 $ 303,103  
Unrealized gain (loss) on long term investments       20,989 22,679  
Syros Pharmaceuticals, Inc.            
License agreements            
Number of program targets | item     7      
Upfront payment under license agreement     $ 10,000      
Fair market value of our long term investments       $ 8,600   5,200
Ownership percentage (as a percent)       3.00%    
Unrealized gain (loss) on long term investments       $ 3,300 $ 3,200  
Syros Pharmaceuticals, Inc. | Stock purchase agreement            
License agreements            
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   0.8        
Purchase price of common stock   $ 10,000        
Per share price | $ / shares $ 9.77 $ 12.61        
Lock-up period 12 months          
Discount for lack of marketability $ 100          
Fair value of shares on the issuance date $ 7,600          
Long term investment           7,600
Research and development expense           2,400
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement            
License agreements            
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares     0.1      
Purchase price of common stock     $ 1,400      
Per share price | $ / shares     $ 9.55      
Long term investment           $ 1,400
Syros Pharmaceuticals, Inc. | Maximum            
License agreements            
Target selection and option exercise fee payment     $ 54,000      
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum            
License agreements            
Additional milestone payments under the license agreement     50,000      
Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum            
License agreements            
Additional milestone payments under the license agreement     $ 65,000      
[1] The condensed consolidated balance sheet at December 31, 2018 has been derived from the audited financial statements at that date.